Back to BIIB

BIOGEN INC. Cash & Equivalents 2006-2026 | BIIB

Beta

What is cash & equivalents?

Cash and cash equivalents can be defined as the most liquid assets on a company's balance sheet, including cash on hand and short-term investments maturing within 90 days.

What is BIOGEN INC.'s current cash & equivalents?

BIOGEN INC. (BIIB) annual cash & equivalents for 2025 was $3.01B, a 26.67% increase from 2024. BIOGEN INC. cash & equivalents for the quarter ending March 31, 2026 was $3.38B.

What was BIOGEN INC.'s cash & equivalents in 2024?

BIOGEN INC. annual cash & equivalents for 2024 was $2.38B, a 126.21% increase from 2023.

What was BIOGEN INC.'s cash & equivalents in 2023?

BIOGEN INC. annual cash & equivalents for 2023 was $1.05B, a 69.29% decline from 2022.

What is BIOGEN INC.'s 5-year cash & equivalents CAGR?

BIOGEN INC. cash & equivalents grew at a compound annual growth rate (CAGR) of 17.71% from FY2020 to FY2025, going from $1.33B to $3.01B over 5 years.

Cash & Equivalents History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Growing
CAGR+17.7%
FY2020
$1.33B
→
FY2025
$3.01B
0607080910111213141516171819202122232425
5 years selected
Cash & Equivalents History
PeriodValueChangeSource
FY2025$3.01B+26.7%10-K
FY2024$2.38B+126.2%10-K
FY2023$1.05B-69.3%10-K
FY2022$3.42B+51.2%10-K
FY2021$2.26B+69.9%10-K
FY2020$1.33B-54.3%10-K
FY2019$2.91B+137.9%10-K
FY2018$1.22B-22.2%10-K
FY2017$1.57B-32.4%10-K
FY2016$2.33B+77.9%10-K
FY2015$1.31B+8.6%10-K
FY2014$1.20B+100.0%10-K
FY2013$602.6M+5.6%10-K
FY2012$570.7M+10.9%10-K
FY2011$514.5M-32.3%10-K
FY2010$759.6M+30.5%10-K
FY2009$581.9M-6.5%10-K
FY2008$622.4M-5.7%10-K
FY2007$659.7M-0.3%10-K
FY2006$661.4M-10-K
Company: BIOGEN INC.Ticker: BIIBSector: HealthcareIndustry: Biological Products, (No Diagnostic Substances)View company profile →